City of Hope and Five Point Holdings, LLC, the largest owner and developer of mixed-use, master-planned communities in coastal California, announced the signing of a memorandum of understanding formalizing a collaboration to build a $200 million, best-in-class, cancer center in Irvine.
Thomas Gallo was named 2018-2019 President of the Association of Community Cancer Centers during its 44th Annual Meeting & Cancer Center Business Summit on March 16.
Heather MackeySusan BruceAnne IrelandHeather Mackey, Susan Bruce, and Anne Ireland were elected to the board of directors in February 2018 were elected by the ONS membership to serve three-year terms with the ONS Board of Directors. Each member could serve part of their terms as president, secretary, or treasurer.
Randi Cohen will join Fox Chase Cancer Center as an associate professor in the Department of Radiation Oncology. She will primarily treat patients at Fox Chase Cancer Center East Norriton Hospital Outpatient Center and provide cancer care services with other Fox Chase specialists at Suburban Community Hospital's cancer center.
The following cancer researchers and clinicians will be recognized for their scientific achievements during the American Association for Cancer Research annual meeting:
Richard and Susan Rogel gave $150 million to the University of Michigan Comprehensive Cancer Center, which will now be known as the Rogel Cancer Center.
NIH has imposed tighter financial controls on researchers at Duke University, citing “ongoing issues” related to management of grants.
Photo courtesy of Research!AmericaThe Research!America 2018 Advocacy Awards Dinner at the Andrew W. Mellon Auditorium March 14On March 14, beneath the soaring ceiling of the Andrew W. Mellon Auditorium, Rep. Nancy Pelosi (D-CA) faced a constellation of round tables at the Research!America 2018 Advocacy Awards Dinner.
GEORGIA REGENTS MEDICAL CENTER received the CEO Cancer Gold Standard accreditation from The CEO Roundtable on Cancer.
Novartis announced the FDA has expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
